Lavie Bio
Lavie Bio Announces Commercial Expansion of Yalos As Seed Treatment for Soybean
Following successful field trials, Lavie Bio intends to commence Yalos sales for soybean in 2025 U.S. spring season.
ICL and Lavie Bio Leverage AI to Advance Development of Biostimulants
More than one dozen novel microbes identified for row crops suffering from extreme weather conditions.
Lavie Bio to Expand Bio-inoculant Yalos to Winter Wheat Across the U.S.
Lavie Bio successfully completed testing of Yalos for winter wheat and will commence sales across the U.S. for the 2024-2025 season.
Bayer and Lavie Bio Extend Joint Validation Trials for Biofungicides
The tests have demonstrated the efficacy of Lavie Bio’s biofungicides in addressing devastating diseases.
Corteva, Lavie Bio Finalize $5 Million Deal for Exclusive AI-Aided Development of Biofungicide
The payment completes the $5M advance payment received under the licensing agreement for biofungicide product candidates.
Lavie Bio Forms Distribution Agreement with WinField United Canada for Its Bio-Inoculant Seed Treatment Yalos
The agreement supports Lavie Bio’s 2024 sales growth plan for spring wheat, durum, and barley in Canada.
Lavie Bio Expands Bio-Inoculant Product for Spring Wheat to Durum and Barley
Lavie Bio will offer Yalos to farmers growing spring wheat, durum and barley across the U.S. and Canada in 2024.
Lavie Bio Advances Biofungicide Toward Commercialization in U.S., Europe Trials
LAV321 delivered positive results in 2023 field trials across Europe and the U.S., protecting against downy mildew.